App-Quantinova.ai

Characterization of cutaneous adverse events to enfortumab vedotin

A. Shahin - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

Cisplatin

Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

T. Okusaka - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cisplatin

Safety and short-term efficacy of preoperative FOLFOX therapy for patients with resectable esophageal squamous cell carcinoma who are not candidates for cisplatin

T. Kadono - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Esophageal squamous carcinoma cell

Cisplatin

Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease

H. Kawakami - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Cisplatin

PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement

G. Abou-Alfa - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cisplatin

HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)

J. Tabernero - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Cisplatin

Different regimens of the 1st line chemotherapy in patients (pts) with metastatic anal cancer: Results of the multicenter observational study

M. Fedyanin - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Cisplatin

FOLFIRI or FOLFOX in second line of advanced biliary tract cancer: A retrospective analysis

M. Balarine - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cisplatin

The impact of second-line treatment after fist-line cisplatin plus gemcitabine in advanced biliary tract cancers: A mono-institutional retrospective study

E. Gurreri - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cisplatin

Combination of gemcitabine plus cisplatin compared to non-gemcitabine and cisplatin regimens as neo-adjuvant treatment in liver transplant recipients with cholangiocarcinoma

M. Abdelrahim - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cisplatin

Feasibility of gemcitabine plus cisplatin as neo-adjuvant in cholangiocarcinoma patients prior to liver transplantation

A. Esmail - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cisplatin

Real-world outcomes of anal cancer patients treated with radical chemoradiation

A. Barbosa - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Cisplatin

Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress

J. Sun - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)

H. Yoon - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

A. He - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cisplatin

Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648

I. Chau - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Cisplatin

Is Platinum-Based Chemotherapy resulted Hypomagnesemia in a Girl with Osteosarcoma? A Case Report

Novina Novina - European Society for Paediatric Endocrinology (ESPE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hypomagnesemia

Cisplatin

Local anesthetics affect tumor biology in an ex vivo tissue model of non-small cell lung cancer

J Krömer - European Society of Regional Anaesthesia & Pain Therapy (ESRA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

INCIDENCE OF ACUTE KIDNEY INJURY IN PATIENTS RECEIVING CISPLATIN AND CARBOPLATIN AND TO EVALUATE ASSOCIATED RISK FACTORS FOR ACUTE KIDNEY INJURY

N. HAPANI - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute renal failure

Cisplatin

A NOVEL SMALL MOLECULAR HSP90 INHIBITOR, C-316-1, ATTENUATES ACUTE KIDNEY INJURY BY SUPPRESSING RIPK1-MEDIATED NECROPTOSIS

X. Liu - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Ischemia-reperfusion injury

Cisplatin

Filters

3952 Abstracts